第三代牛心包主动脉瓣生物瓣的中期耐久性与血流动力学:莱比锡经验
该研究回顾性分析了918例接受Trifecta主动脉瓣置换术患者的资料,随访平均2.7年。结果显示植入安全,5年结构性瓣膜衰败免除率为97.9%±1.5%,血流动力学表现良好,平均跨瓣压差从基线39.3 mmHg降至6个月时9.4 mmHg。
要点
- Trifecta瓣膜植入安全,围术期并发症可控。
- 中期随访5年结构性瓣膜衰败免除率达97.9%±1.5%。
- 血流动力学改善显著,平均跨瓣压差从39.3 mmHg降至9.4 mmHg。
核心结论
- Trifecta瓣膜在大样本单中心队列中显示植入简便安全、血流动力学性能良好且中期耐久性满意。
研究设计与样本
- 回顾性分析918例接受主动脉瓣置换术患者的单中心队列数据,平均年龄73.2±6.5岁,logistic EuroSCORE为13.2±14.3。
主要发现
- 54.9%的患者同期行其他手术;低心排综合征发生率为4.3%,术后出血需输血或再手术为7.0%,急性肾衰竭需临时透析为11.7%。
- 出院时44例(4.8%)存在中度瓣膜-患者不匹配(PPM),无重度PPM。
- 平均随访2.7±1.6年(最长7.4年);全部患者和单纯主动脉瓣置换患者的30天生存率分别为88.7%和92.0%,5年总生存率分别为73.4%和82.2%。
- 心肌梗死(OR 78;95%CI 20.8-294)和正性肌力药物使用(OR 6.8;95%CI 3.2-14.5)是长期死亡的最强独立预测因素。
- 5年结构性瓣膜衰败(SVD)免除率为97.9%±1.5%;左心室射血分数(LVEF)术后与基线相似且稳定(范围58.9%-62.3%);平均跨瓣压差从基线39.3 mmHg改善至6个月时9.4 mmHg。
临床怎么用
- Trifecta瓣膜可用于主动脉瓣置换,中期耐久性和血流动力学表现支持其临床应用。
局限性
- 本研究为单中心回顾性分析,随访时间有限(平均2.7年,最长7.4年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Trifecta valve (St. Jude Medical, St. Paul, MN) is a stented bovine pericardial bioprosthesis for aortic valve replacement (AVR). Implantation experience and midterm follow-up of this valve have not yet been reported from a large single-center cohort. METHODS: We retrospectively analyzed data from 918 patients (73.2 ± 6.5 years; logistic European System for Cardiac Operative Risk Evaluation [EuroSCORE], 13.2 ± 14.3) who underwent AVR. Analyses addressed implantation safety, short- and long-term survival, and hemodynamic valve performance. RESULTS: Concomitant procedures were performed in 54.9% of the patients. Low cardiac output syndrome, postoperative bleeding requiring transfusion or reoperation, and acute renal failure requiring temporary hemodialysis occurred at rates of 4.3%, 7.0%, and 11.7%, respectively. At discharge, 44 patients (4.8%) were identified with moderate prosthesis-patient mismatch (PPM) and none was identified with severe PPM. Mean follow-up was 2.7 ± 1.6 years (maximum, 7.4 years). Survival at 30 days was 88.7% and 92.0% for all patients and patients with isolated AVR, respectively; 5-year overall survival for these groups was 73.4% and 82.2%, respectively. Myocardial infarction (odds ratio [OR], 78; 95% confidence interval [CI], 20.8-294) and inotropic medication (OR, 6.8; 95% CI, 3.2-14.5) were the strongest independent predictors for long-term mortality. Five-year freedom from structural valve deterioration (SVD) was 97.9% ± 1.5%. Left ventricular ejection fraction (LVEF) after implantation was similar to baseline and was stable over time (range, 58.9%-62.3%). The mean gradient improved substantially (39.3 mm Hg at baseline versus 9.4 mm Hg at 6 months). CONCLUSIONS: This large single-center cohort shows the easy and safe implantation, adequate hemodynamic performance, and satisfactory durability of the Trifecta valve at midterm follow-up.
引用
- Lehmann S, Meyer A, Schroeter T, et al. Midterm Durability and Hemodynamic Performance of a Third-Generation Bovine Pericardial Prosthetic Aortic Valve: The Leipzig Experience. Ann Thorac Surg. 2016. PMID: 27955900. doi:10.1016/j.athoracsur.2016.09.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。